ArchiveMarch 2015

Another growth factor for oligodendrocytes

Hammond E, Lang J, Maeda Y, Pleasure D, Angus-Hill M, Xu J, Horiuchi M, Deng W, Guo F. The Wnt Effector Transcription Factor 7-Like 2 Positively Regulates Oligodendrocyte Differentiation in a Manner Independent of Wnt/β-Catenin Signaling.J Neurosci. 2015;35:5007-22. Genetic or pharmacological activation of canonical Wnt/β-catenin signaling inhibits oligodendrocyte differentiation. Transcription...

Spinal fluid neurofilament levels: effective DMTs stops nerve damage

Spinal neurofilament levels are ready for prime time. #MSBlog #MSResearch “The following study supports spinal fluid neurofilament levels as surrogate marker of neuroaxonal damage and loss in MS. Levels were raised at baseline and decreased during the study, but it was only significant in MSers on fingolimod. Why did levels drop in MSers on placebo? We call this regression to the mean. When...

Cognition in Progressive MS – a hard nut to crack!

J Neurol Sci. 2015 Mar 3. pii: S0022-510X(15)00124-0. doi: 10.1016/j.jns.2015.02.044. [Epub ahead of print] Orienting network dysfunction in progressive multiple sclerosis. Ayache SS, Palm U, Chalah MA, Nguyen R, Farhat WH, Créange A, Lefaucheur JP. Among patients with multiple sclerosis (MS), cognitive impairment affects up to 70% of the population . The most frequently impaired domains are...

Comorbidities: MS and cancer risk

MSers may have a higher incidence of developing bladder cancer. #MSBlog #MSResearch “The following meta-analysis is the next in a recently published series of papers by Ruth-Ann Marrie and colleagues. It suggests MSers have a higher incidence of urinary tract cancers and meningiomas than the general population. The higher incidence of meningiomas is likely to be explained by ascertainment...

Cortical; Relapses

Puthenparampil M, Poggiali D, Causin F, Rolma G, Rinaldi F, Perini P, Gallo P.Cortical relapses in multiple sclerosis. Mult Scler. 2015. pii: 1352458514564483. [Epub ahead of print] BACKGROUND:Multiple sclerosis (MS) is a white and grey matter disease of the central nervous system (CNS). It is recognized that cortical damage (i.e. focal lesions and atrophy) plays a role in determining the...

Breast feeding and MS

Ragnedda G, Leoni S, Parpinel M, Casetta I, Riise T, Myhr KM, Wolfson C, Pugliatti M. Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study.J Neurol. 2015. [Epub ahead of print]Breastfeeding for at least 4 months has been found to be associated with a reduced risk of immune-mediated diseases...

Progressive MS trials are like buses you wait ages for one and then two come at the same time

Whilst  I appreciate that maybe our car-loving readers may not get the concept of two buses coming at the same time when you have been waiting ages for one, it is funny that this is just what is happening in progressive MS.  We have to take the 55 bus or the 205 bus each day or walk 2-3 miles (~4-5km) to see the beasties, some times multiple times a day The idea of MS-SMART trials was...

My biomarker wishlist for the MS-SMART study

Those of you I met and talked to at the ‘MS Research Day’ on the 21.3.2015 would already know that my field of work is on biomarkers – specifically biological markers found in bodily fluids. A biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a...

MS Comorbidities Toronto 2015

My comorbidity talk from the NMSS-ECTRIMS meeting in Toronto. #MSBlog #MSResearch “As promised the following is my presentation from the NMSS-ECTRIMS comorbidities meeting in Toronto. I found preparing this presentation very difficult. I am sure I delivered on the brief. Overall the meeting made me think a lot of about how we treat MS and I will now need to update my comorbidities line on...

How do like your pills?

Wicks P, Brandes D, Park J, Liakhovitski D, Koudinova T, Sasane R.Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients. Interact J Med Res. 2015;4(1):e6. doi: 10.2196/ijmr.3776. BACKGROUND:Oral disease modifying therapies (DMTs) for multiple sclerosis (MS) differ in efficacy, tolerability, and safety...

Translate

Categories

Recent Posts

Recent Comments

Archives